Passage Bio, INC

Passage Bio has terminated its research collaboration with Gemma Biotherapeutics and exited its Philadelphia office lease, incurring a $2.3 million termination fee.

Passage Bio, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Passage Bio is implementing a significant restructuring, reducing its workforce by approximately 75% to decrease operating expenses as it reviews strategic alternatives.

Passage Bio announced updated interim data from its PBFT02 trial for FTD-GRN, showing reduced brain atrophy and stabilized NfL, but faces FDA requirement for a randomized trial, prompting a strategic review.

Passage Bio announced its full-year 2025 financial results and provided key updates on its clinical programs for frontotemporal dementia and preclinical work for Huntington's disease.

Passage Bio, Inc. reported preliminary unaudited cash of approximately $46 million as of December 31, 2025, extending its cash runway into Q1 2027, alongside positive interim clinical data for its FTD-GRN gene therapy, PBFT02.

Passage Bio's Q1 2026 Form 10-Q filing details ongoing clinical development, a significant workforce reduction, and the initiation of a strategic alternatives review, while highlighting substantial doubt about its going concern.

Passage Bio, a genetic medicines company, reported reduced net losses and extended its cash runway into the first quarter of 2027, driven by strategic restructuring and workforce reductions, while advancing its lead FTD-GRN gene therapy.

Passage Bio reported a reduced net loss and extended its cash runway into Q1 2027, driven by cost-cutting measures and strategic out-licensing, despite ongoing clinical trial risks and the impact of a recent reverse stock split.

Passage Bio reports a net loss of $15.4 million for Q1 2025 and provides updates on its clinical programs, including PBFT02 for FTD-GRN and FTD-C9orf72.

Passage Bio announced its third quarter 2024 financial results, highlighted by a strategic outlicensing of several programs to Gemma Biotherapeutics and a restructuring of its research collaboration with Penn.

Passage Bio announced its second quarter 2024 financial results and a strategic outlicensing agreement with Gemma Biotherapeutics for several key programs.

Passage Bio reports continued operating losses in its 2025 annual filing, advancing its lead gene therapy candidate PBFT02 for neurodegenerative diseases while navigating financial and operational challenges.

Passage Bio focuses on PBFT02 development for neurodegenerative diseases after out-licensing pediatric programs.

Passage Bio's 10-K filing highlights a strategic shift towards neurodegenerative diseases, prioritizing PBFT02 development and exploring out-licensing opportunities for pediatric programs.

Passage Bio and Remix Therapeutics announce a merger aimed at advancing Remix's RNA processing platform and oncology drug candidates, with a concurrent $100M financing.

Lynx1 Capital Management LP and Weston Nichols report acquiring a significant stake in Passage BIO, Inc. through multiple share purchases.

Passage Bio and Remix Therapeutics have entered into a definitive merger agreement, supported by a $100M private placement, to advance RNA-targeted therapies.

Passage Bio and Remix Therapeutics have entered into a definitive merger agreement to combine in an all-stock transaction, with the combined company focusing on Remix's RNA-targeted small molecule pipeline.

Director Dolan Sondhi acquired stock options for 10,539 shares of Passage BIO, Inc. (PASG) with an exercise price of $5.08, vesting under specific service conditions.

Passage BIO reports a Form 4 filing detailing director Derrell Porter's acquisition of stock options.

Passage Bio has announced its 2026 virtual annual meeting to elect directors, ratify auditors, and conduct advisory votes on executive compensation.

Passage Bio, Inc. sets date for its 2025 Annual Meeting and encourages stockholders to vote on key proposals, including director elections, auditor ratification, and a potential reverse stock split.

Passage Bio is asking stockholders to approve a reverse stock split to boost its share price and maintain its Nasdaq listing.

Passage Bio, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on May 21, 2024, outlining key proposals for shareholder voting.

Passage Bio, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on May 21, 2024, to elect directors and ratify the appointment of KPMG LLP as its independent accounting firm.

Lynx1 Capital Management LP and Weston Nichols have disclosed a beneficial ownership of 21.0% of Passage BIO, Inc. common stock, totaling 673,759 shares, following recent transactions and in anticipation of a merger with Remix Therapeutics.

OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC have filed an exit Schedule 13D, reporting a decrease in their beneficial ownership of Passage BIO, Inc. common stock to below 5%.

OrbiMed Advisors and OrbiMed Capital GP VII have reduced their beneficial ownership in Passage Bio, Inc. to 7.82% after a series of share sales and a 1-for-20 reverse stock split.

OrbiMed Advisors and OrbiMed Capital GP VII have significantly reduced their beneficial ownership in Passage BIO, Inc. to 9.5% through a series of share sales in late June and early July 2025.

OrbiMed Advisors and OrbiMed Capital GP VII LLC have filed an Amendment No. 6 to their Schedule 13D, reporting a decrease in their beneficial ownership of Passage BIO, Inc. common stock to 10.7% following recent share sales.

Baselake Partners, LP, Baselake Management, LLC, and David Paolella have filed a Schedule 13G reporting a 7.3% beneficial ownership stake in Passage Bio, Inc.

Lynx1 Capital Management LP and Weston Nichols have disclosed a significant beneficial ownership stake of 19.6% in Passage BIO, Inc., holding 623,704 shares.

Lynx1 Capital Management LP and Weston Nichols have reported a 15.0% beneficial ownership stake in Passage BIO, Inc., holding 9,256,953 shares of common stock as of December 31, 2024.